Open access peer-reviewed chapter

Isoflavones: Vegetable Sources, Biological Activity, and Analytical Methods for Their Assessment

Written By

Daniela-Saveta Popa and Marius Emil Rusu

Submitted: 24 May 2016 Reviewed: 25 October 2016 Published: 22 February 2017

DOI: 10.5772/66531

From the Edited Volume

Superfood and Functional Food - The Development of Superfoods and Their Roles as Medicine

Edited by Naofumi Shiomi and Viduranga Waisundara

Chapter metrics overview

2,903 Chapter Downloads

View Full Metrics

Abstract

Phytoestrogens are natural compounds found in various plant species and they have the ability to bind to the estrogenic receptors, exerting agonist and/or antagonist effects. The main classes of phytoestrogens are isoflavones, lignans, and coumestranes. Isoflavones are plant bioactive nonsteroidal polyphenolic metabolites with antioxidant properties. They have a very close structure with 17β-estradiol and possess estrogenic/antiestrogenic effects. The main dietary source of isoflavones is soy (Glycine max L.). Other legumes, such as red clover (Trifolium pratense L.), alfalfa (Medicago sativa L.), and Genista species, have important content in isoflavones, showing nutritional or phytotherapeutic interest. In plants, isoflavones can be found mainly as non-active glycosides which are converted after ingestion, in the corresponding aglycones (e.g., genistein, daidzein) that have pharmacological activity. Many studies have demonstrated the benefits of dietary isoflavones in menopause and multiple chronic pathologies, including cardiovascular diseases, osteoporosis, and hormonal cancers. Dietary intake of isoflavones is widespread, mainly due to the consumption of soybean products. Analytical methods applied for the quantification of isoflavones allow both assessment of dietary intake of isoflavones and highlighting natural sources with phytotherapeutic potential. Health benefits of isoflavones justify the interest for this class of functional food; therefore, further clinical and epidemiological studies are required.

Keywords

  • nutraceuticals
  • phytoestrogens
  • isoflavones
  • vegetables
  • analysis

1. Introduction

Phytoestrogens are natural nonsteroidal compounds able to bind to estrogenic receptors and have both estrogenic and antiestrogenic activities. They are widespread in the plant kingdom being considered ubiquitous. The main classes of phytoestrogens are isoflavones, coumestans, and lignans.

Isoflavones are plant-derived secondary metabolites with a polyphenolic structure and antioxidant properties [1]. They pertain to the flavonoid class and are found mostly in plants belonging to Fabaceae family. Soy (Glycine max L.) is the major natural source of isoflavones, and the benefits associated with a soy diet occur mostly because of these phytochemicals. Other natural sources of isoflavones are red clover (Trifolium pratense L.), alfalfa (Medicago sativa L.), and species of the genus Genista. All of these plants present phytotherapeutic and nutraceutical significance, and their by-products, herbal teas, and food supplements are often used.

Several epidemiological studies have demonstrated the benefits of dietary isoflavones in menopause and multiple chronic pathologies, including cardiovascular diseases, osteoporosis, and hormonal cancers. The main mechanisms of action of isoflavones, their benefits to human health, and the factors involved in the modulation of their bioactivity are shown in this chapter. Moreover, the analytical methods used for their quantification in plant and food samples are introduced. These are very important methods to evaluate the human exposure to isoflavones and also to assess the optimum intake for human well-being.

Advertisement

2. Characteristics of isoflavones

2.1. Chemistry and metabolism of isoflavones

Isoflavones (IFs) are yellow pigments derived from 3-phenyl-benzopyrone (3-phenyl-chromone) structure. They are found in plants mostly as biologically inactive glycosides: 7-O-β-D-glycosides, 6″-O-acetyl-7-O-β-D-glucosides, and 6″-O-malonyl-7-O-β-D-glycosides [1, 2]. After ingestion, glycosides are not bioavailable to be absorbed through enterocytes [3]. They are hydrolyzed into bioactive aglycones by both intestinal mucosa and bacterial β-glucosidases from the gut microbiota. Only these forms are absorbed into systemic circulation directly or after subsequent metabolism in the bowel by intestinal bacteria [3]. Soybeans incorporate predominantly genistin, daidzin, and glycitin as inactive glycosides, which are hydrolyzed into their corresponding biologically active aglycones: genistein, daidzein, and glycitein. Other isoflavones observed in legumes are ononin and sissotrin, with their aglycones, formononetin, and biochanin A, respectively (Figure 1).

Figure 1.

Chemical structure of main isoflavones.

The absorption of aglycones is fast and efficient. Plasmatic isoflavone levels increase up to micromolar-level values after the consumption of soy-based foods, compared to the nanomolar (≤40 nm) levels found in diets without soy [4]. First pharmacokinetic study on isolated and purified isoflavones was performed, when a single dose of 50 mg of aglycone or the equivalent dose of β-glycoside, respectively, was given to healthy adult volunteers. The plasmatic peak values (Cmax) were 341 ± 74 ng/mL for genistein and 194 ± 30.6 ng/mL for daidzein. The times when the values reached the peaks were 5.2 and 6.6 hours (tmax) in the case of direct aglycones ingestion and 9.3 and 9.0 h in the case of the ingestion of β-glycosides, genistin, and daidzin, due to the time required for their hydrolysation. The bioavailability of genistein and daidzein (based on the area under the curve in plasma concentration versus time graph) was higher after consumption of β-glycosides [5].

Formononetin and biochanin A can be transformed to daidzein and genistein, respectively, through 4′-O-demethylation by the gut microflora or in the liver [6]. Aglycones can be further metabolized through several steps: reduction, deoxygenation, hydroxylation, and C-ring cleavage. Daidzein forms S-(−)equol and O-desmethylangolensin (O-DMA) via dihydrodaidzein (Figure 2). Similarly, genistein is metabolized first as dihydrogenistein and then as 5′-hydroxy-equol and p-ethyl phenol (Figure 2). Another possible minor pathway is the hydroxylation of isoflavone rings at different positions, catalyzed by hepatic cytochrome P450 isoenzymes [2]. Metabolites with phenolic or polyphenolic structures are conjugated to O-glucuronides and sulfate esters during and after absorption through the gut barrier and more intense in the liver. The conjugated metabolites are urinary or biliary excreted and have enterohepatic circulation [4, 7].

Figure 2.

Metabolic pathways of daidzein and genistein.

Gut microbiota play a very important role in the isoflavone metabolism. The positive effects of a soy-rich diet derive from the existence of microorganisms in the gut capable of intense metabolization of isoflavones. It is the so-called equol producer phenotype, responsible for metabolizing daidzein to equol and identified through the equol/daidzein ratio in the 24-hour urine. Asian people (Japanese, Korean, or Chinese) and Western adult vegetarians are 50–60% equol producers, but equol producers are only 25–30% in Western population. This phenotype is rather stable and cannot be modulated through prebiotic or probiotic nutritional interventions [8]. Otherwise, there are differences between human and animal metabolism, and therefore in vivo results are not relevant to humans [9]. All tested animals had equol in urine after the ingestion of soy or clover [8]. Notably in rodents, equol constitutes 70–90% from the serum isoflavones, compared to humans where only 30% of the daidzein absorbed is metabolized as equol [4].

2.2. Isoflavone content in different sources

Isoflavones can be found in legumes [1012], nuts, and some fruits, such as currants and raisins [13], coffee [14], and cereals [15], but the most important dietary sources are soybeans and their by-products [10, 12]. The content of isoflavones in several plants and foods is presented in Tables 1 and 2. Soy can be ingested as textured soy protein, as soy milk or drink, added to many fortified foods (e.g., energized bars, cereals, baby formula), or consumed as fermented soybean products, such as miso, natto, and tempeh (Table 3) [12]. Also, many food supplements containing soy isoflavones are on the market [16].

Food descriptionDaidzeinGenisteinGlyciteinTotal IFs
Soybeans, green, mature seeds, raw61.7060.077.07128.83
Soybeans, mature seeds, raw (the mean values from Australia, Brazil, China, Europe, Japan, Korea, Taiwan, the USA)62.07 (27.77–78.86)80.99 (39.78–89.32)14.99 (9.01–22.37)154.53 (85.68–178.81)
Soybeans, mature seeds, cooked, boiled30.7631.263.7565.11
Beans, common, raw (Phaseolus vulgaris)0.290.300.000.59
Beans, adzuki, mature seeds, raw0.360.230.000.59
Beans, pinto, mature seeds, raw0.010.17-0.18
Black bean, sauce5.964.040.5310.26
Chickpeas, mature seeds, raw0.210.060.180.38
Chickpeas, mature seeds, cooked, boiled0.000.02-0.02
Peas, green, split, mature seeds, raw0.320.110.000.44

Table 1.

Isoflavone content in selected legumes (mg/100 g, edible portion—the mean value derived from multiple experiments) [12].

Food descriptionCoumestrolFormononetinBiochanin A
Egg, whole, raw, fresh0.000.050.05
Alfalfa seeds, sprouted, raw1.601.430.04
Clover sprouts, raw14.083.150.59
Red clover1322.00833.00-
Soybeans, mature seeds, raw0.028.460.00
Soybeans, mature seeds, sprouted, raw0.340.030.00
Lima beans, large, mature seeds, raw0.140.320.27
Lima beans, large, mature seeds, boiled0.000.010.00
Chickpeas, mature seeds, raw0.010.121.54
Chickpeas, mature seeds, canned0.000.00-

Table 2.

Coumestrol, Formononetin, and Biochanin A in selected foods (mg/100 g, edible portion—the mean value derived from multiple experiments) [12].

Food descriptionDaidzeinGenisteinGlyciteinTotal IFs
Miso16.4323.243.0041.45
Natto33.2237.6610.5582.29
Tempeh22.6636.153.8260.61
Tofu, raw, regular, prepared with calcium sulfate8.5612.991.9822.73
Soybeans, green, raw (includes edamame)20.3422.577.5748.95
Soybeans, green, cooked, boiled, drained, without salt (includes edamame)7.417.064.6017.92
Soybeans, mature seeds, sprouted, raw12.8618.772.8834.39
Instant beverage, soy, powder, not reconstituted40.0762.1810.90109.51
Soy cheese, unspecified5.7911.14-25.72
Soy drink2.755.10-7.85
Soy flour (textured)67.6989.4220.02172.55
Soy meal, defatted, raw80.77114.7116.12209.58
Soy protein drink27.9842.9110.7681.65
Soy protein isolate30.8157.288.5491.05
Soy yogurt13.7716.592.8033.17

Table 3.

Isoflavone content in soy foods (mg/100 g, edible portion—the mean value derived from multiple experiments) [12].

Isoflavone content in plants can vary greatly (up to threefold) for the same variety by growth conditions, geographical areas, years, biotic stress factors (e.g., pests), and abiotic stress factors, such as temperature, nutritional status, or drought [4]. Dietary culture has an especially big influence on isoflavone content in the diet. Asian and vegetarian diets provide 20–50 mg isoflavones/day, in some cases reaching 100 mg/day, while the Western diet contributes only 0.2–1.5 mg isoflavones/day [2]. Based on recent report of European Food Safety Authority (EFSA), in Europe the dietary isoflavone intake is usually under 1 mg/day, despite an increase in the soy food consumption [17]. The differences between the types of diets refer to the amount of isoflavone in foods, as well as the type of food consumed. In the Western diet, solid processed soy products (such as tofu) and soymilk dominate the diet, and they contain both glycosides (genistin and daidzin which are stable during processing) and aglycones. In the Asian diet, most soy products are obtained through fermentation and have higher amounts of aglycones [3]. Miso, fermented soybean paste (Japan); doenjang, fermented soybean paste (Korea); douchi, fermented soybeans (China); and tempeh, fermented soybean cake (Indonesia) are staple foods in some Asian countries. Simultaneously, health benefit probiotics are formed in these foods during the fermentation processes [18].

Besides soy, other plants in the Fabaceae family have a high content of isoflavones: species of clover, mainly red clover (Trifolium pratense L.), alfalfa (Medicago sativa L.), and hop clover (Medicago lupulina L.), form important part of animal feed. These plants are used in phytotherapy, as medicinal teas or as food supplements. Red clover (Trifolium pratense L.) incorporates mainly genistein, daidzein and formononetin, and their respective β-glycosides [1922]. It also contains important quantities of coumestrol, a phytoestrogen part of coumestan class [19, 20], and antioxidant compounds [23, 24]. Data from scientific literature show that red clover extracts can be used as replacement for conventional hormonal therapy in menopause or hormone-dependent diseases [25]. Alfalfa (Medicago sativa L.) contains isoflavones (genistein, daidzein, formononetin, biochanin A) in addition to other phytoestrogens (coumestrol) and many nutrients. It is used in phytotherapy for its antianemic, antihemorrhagic, and remineralization properties [26] and for its hypocholesterolemic, antimicrobial, hypolipidemic, antioxidant, antiulcer, neuroprotective, and estrogenic properties [27]. Species of Genista (G. tinctoria L., G. sagittalis L.) contain essentially genistin and genistein [19, 20, 28, 29]. They are known for their hypoglycemic [30], anti-inflammatory, antiulcer, spasmolytic, antioxidant, and estrogenic properties [31]. Among these plants, Genista tinctoria L. show antioxidant and antitoxic activities [32, 33], protective effect against ultraviolet (UV) radiation, and in vitro melanoma cell proliferation [31].

2.3. Mechanism of estrogen-like action of isoflavones

According to the xenohormesis theory, plants synthesize phytochemicals to withstand and adapt under stress. Indeed, isoflavone biosynthesis depends on the environmental conditions in which the plant grows and is stimulated by stress. The stress-induced plant compounds have the ability to upregulate stress adaptive pathways in animals and humans. In the body, the biological effects of isoflavones are exercised by modulating pathways mediated by estrogen receptors (ERs) or various key enzymes involved in cellular signaling or metabolism and antioxidant potential [4].

Advertisement

3. The estrogenic/antiestrogenic effects

Isoflavones produce both estrogenic and antiestrogenic effects through several ways. Due to their structure similar to that of 17β-estradiol, they have the ability to bind to the nuclear ERs, but their affinity for these receptors is rather weak. Only genistein shows stronger affinity for ERβ to which it binds preferentially. Its relative affinity (0.87) is closer to that of the reference hormone, 17β-estradiol. Daidzein affinity for these receptors is 0.005, but equol, its metabolite, has a 5.7 times stronger affinity, thus increasing its estrogenic potential. The affinity for ERα decreases as follows: genistein > equol > daidzein, with the values of 0.04, 0.005, and 0.001, respectively. The affinities of other isoflavones are less than 0.0001 [2, 4].

Isoflavones induce agonist/antagonist effects depending on the level of the endogenous estrogen. For people with high levels of estrogen, (women premenopause, especially in the follicular phase of the menstrual cycle), the isoflavones bind to the estrogen receptors. Because of their weak estrogen potency, isoflavones exert an antagonist effect. They block the action of endogenous estrogens on their receptors. In case of low concentration of endogenous estrogens (women in menopause, after ovariectomy, or males), the estrogenic action of isoflavones becomes evident, showing additive agonist effect [34]. This is the reason why isoflavones can be used as a long-term complementary or alternative hormone therapy [35].

Isoflavones and their active metabolites can bind to the membrane ERs and induce rapid non-genomic effects by which they modulate cellular metabolism. Thus, they can change the protein kinase and lipid kinase cell signaling pathways [1]. It is believed that the activation of these signaling pathways by isoflavones causes some beneficial effects, in particular in the tissues that are not specific targets for the estrogens. At the circulatory system, the isoflavones induce vasodilation by increasing the production of nitric oxide (NO) after the activation of the endothelial NO synthase. At the central nervous system, they improve the cognitive function by affecting cell membrane permeability and altering the neuronal excitability. In the skeletal system, the isoflavones inhibit the tyrosine kinase causing changes in the alkaline phosphatase activity. On the other hand, they induce the apoptosis of the osteoclasts, suppress the formation of osteoclasts [34], and prevent the bone demineralization [35].

Also, isoflavones influence the activity of some of the enzymes involved in the metabolism of the sex steroid hormones. In this way they inhibit 5α-reductase (the enzyme responsible for the conversion of testosterone to 5α-dihydrotestosterone) and aromatase (involved in the conversion of testosterone to estradiol) in low concentrations, but they increase the aromatase activity at high concentrations. Isoflavones have an affinity for sex hormone-binding globulin (SHBG) and they induce its expression. Therefore, they affect the free-steroid hormone level in the systemic circulation. But these outcomes depend on many factors, including species, gender, and the hormonal status [35].

Xenoestrogens can modulate the enzyme activity of aromatase. Thus, they induce alterations in the metabolism of fats and carbohydrates through effects on ERα. The decrease of endogenous estrogen levels on ERα, aromatase inhibition or the existence of mutations affecting the enzyme activity has been correlated with visceral obesity or truncate, hyperlipidemia, glucose intolerance and insulin resistance, low physical activity, and reduced energy expenditure. Isoflavones compensate for the deficit of estrogens and have the ability to prevent the associated negative effects. Asian diets, rich in isoflavones, are correlated with low incidence of obesity and metabolic syndrome, favorable plasma profile, and a reduced body mass index in postmenopausal women [4].

Advertisement

4. Health benefits of isoflavones

4.1. Isoflavones and their effects on diseases

Numerous epidemiological and clinical studies have demonstrated the protective role of dietary isoflavones against development of specific menopause symptoms [3638] and several chronic diseases, including cardiovascular diseases [39, 40], osteoporosis [38], cognitive impairment [37], and hormone-dependent cancers [4143]. Based on human health benefits of soy diet, the Food and Drug Administration (FDA) approved the use of the following health claim on the labels: “25 grams of soy protein a day, as part of a low in saturated fat and cholesterol, may reduce the risk of heart disease” [44].

Isoflavones, as all polyphenols, have a strong antioxidant activity. They can neutralize free radicals and prevent the lipid peroxydation by stopping the chain reactions. Also, isoflavones induce the antioxidant enzymes (glutathione peroxidase, catalase, and superoxide dismutase) and inhibit the expression of some enzymes, such as xanthine oxidase [1]. The antioxidant protective action of isoflavones from soy or plant extracts, such as Trifolium pratense L. or Genista tinctoria L., was proven in clinical studies [45, 46], as well as in animal models [32, 47].

4.2. Anticarcinogenic activity of isoflavones

The anticarcinogenic potential of isoflavones is based on multiple actions: binding to estrogen receptors (ERs), changing of cell signaling pathways, and inhibition of the key enzymes involved in the metabolism of sex hormones. Also, the anticarcinogenic potential of isoflavones has positive effects through independent mechanisms which do not involve ERs, such as antioxidant activity, reduction in the bioactivation of carcinogens, and stimulation of detoxification [2, 48].

Anticarcinogenic activity of genistein has been assessed more thoroughly among isoflavones. Genistein initiates apoptosis, alters cell proliferation and angiogenesis, and inhibits metastasis in many types of cancer cells [49]. It is a tyrosine kinase inhibitor. Therefore, in breast cancer cells, it slows down tumorigenesis; in the circulatory system, it prevents tumor vascularization; in the nervous system, it induces neuroprotective effects. In addition, genistein affects tumorigenesis by inhibiting DNA topoisomerases I and II [50], alteration of epigenetic regulations (both histone methylation and DNA methylation), and activating tumor suppressor genes [51]. As a polyphenol, genistein has antioxidant [1] and anti-inflammatory potential [52]. Another possible action pathway for genistein is the competitive inhibition of estrone metabolism through cytochrome P450 isoenzymes by altering the 2-hydroxy-estrone (2-OH-E1)/16α-hydroxy-estrone (16α-OH-E1) ratio, as noticed in vitro [53]. While 2-OH-E1 is a weak estrogen, 16α-OH-E1 has an important role in carcinogenesis, showing a strong estrogen effect and genotoxic properties [54]. 16α-OH-E1 covalently binds to the estrogenic receptors and thus stimulates cell proliferation [55]. The ratio 2-OH-E1/16α-OH-E1 has been proposed and studied as a biomarker of breast cancer risk [5559], but now its significance is controversial. In high concentrations, genistein decreases the hydroxylation of estrone in position 2 in favor of hydroxylation in position 16α [55]. Other studies show that genistein has no mutagenic or clastogenic activity in vivo. But in high concentration of genistein, it has clastogenic potential in vitro, explained by the topoisomerase inhibitory effect, which is known to cause chromosome damage above a certain threshold dose [60].

Anti-proliferative effects of high concentrations of genistein were demonstrated in all breast cancer cells, both ER positive and ER negative. However, there are several studies showing that genistein shows both anti-proliferative and proliferative effects, depending on the concentration, type of tumor, level of endogenous estrogens present in the tissue, or development stage. At low physiological concentrations, genistein stimulates tumorigenesis and cancels the effects of tamoxifen in ER-positive breast cancer cells [50]. Similar dual effects were observed in the case of tamoxifen and other selective estrogen receptor modulators (SERMs) [16].

In fermented soybean products (e.g., natto, miso, tempeh), aglycons can suffer changes under the effect of enzymes produced by the microorganisms involved in the fermentation process. Thus, ortho-hydroxygenistein (6-OHG, 8-OHG, 3′-OHG) and ortho-hydroxydaidzein (6-OHD, 8-OHD, 3′-OHD) were identified. These compounds are not synthesized by the plants. The hydroxylation reaction that occurs in the ortho position gives molecules a high antioxidant potential and a free radical scavenging activity. Moreover, several of their abilities have been proven: to suppress cell proliferation and to inhibit tyrosinase (anti-melanogenesis properties) and antimutagenic, anti-inflammatory, and hepatoprotective properties [18].

Equol has a higher estrogenic potential than daidzein, its precursor, and a preferential affinity for ERβ, as it has already been stated. This detail is of high interest for its beneficial effect in the treatment of prostate cancer, since both isomers, S-(−)equol and R-(+)equol, can bind in vivo dihydrotestosterone without having an affinity for the androgen receptor. Therefore, equol prevents the endogenous hormone to exert its stimulating effect on prostate growth. In addition, equol possesses the highest antioxidant capacity of all isoflavones tested. It causes blood vessel relaxation and modifies the inflammatory response in activated macrophages and has beneficial effects in cardiovascular and inflammatory diseases [52].

4.3. Effects of isoflavones on hormone-dependent cancers

Clinical studies show contradictory results of the efficacy of isoflavones in the treatment of breast cancer. The effects depend on a number of factors such as age, gender, hormonal status, type of isoflavones consumed (soy proteins or isolated isoflavones), dose, diet (type of food), and extent of consumption [2].

A recent meta-analysis of 35 studies shows that soy isoflavones lower the risk of breast cancer in both premenopausal and post-menopausal women. The effect is more evident in Asian women than in those living in Western countries, probably due to differences in quality (traditionally fermented foods) and quantity of the isoflavone products ingested [41]. In Asian women, a diet rich in soy food lowers breast cancer risk with 30% [61]. A higher prevalence of equol-producer phenotype in Asian population can be an essential factor. Equol-producer phenotype is associated with a substantial reduction in the risk of breast cancer. Several specific biomarkers are favorable modified, such as sex hormone-binding globulin (SHBG) and steroid hormone levels in plasma, a higher urinary 2-hydroxy-estrone/16α-hydroxy-estrone ratio, and a lower mammographic breast density [2]. However, because several studies have provided mixed or contradictory results, the general recommendation for patients diagnosed with estrogen-dependent breast cancer is to avoid consuming high quantities of products containing isoflavone. Indeed, isoflavones are selective estrogen receptor modulators (SERMs), and their effects would depend on multiple factors.

Another meta-analysis of five cohort studies that included more than 11,000 female patients diagnosed with breast cancer focused on the post-diagnostic relationship between consumption of soy foods and mortality or cancer recurrence. The study concluded that the ingestion of soy foods reduced mortality and recurrence in all types of breast cancer, especially in the ER-negative, ER-positive/PR-positive, and postmenopausal patients [42]. In women diagnosed with breast cancer under tamoxifen treatment, the consumption of plants containing isoflavones did not alter plasma levels of the drug and its metabolites [62]. Moreover, a recent study shows that a moderate intake of soy isoflavones (5–10 g soy protein/day) would have an optimal effect on tamoxifen treatment on these patients [63].

In some studies [64], excessive consumption of soy was associated with a negative impact on male fertility and reproductive hormones and the disruption of the thyroid gland function. In other studies these effects were inconsistent [65].

Isoflavones can modulate the toxicity of other xenoestrogens, but the interactions are complex and difficult to predict relying only on in vitro steroid receptor affinities [66]. In these kinds of interactions, multiple mechanisms are involved, both estrogen and non-estrogen type, such as oxidative stress [32, 47, 53]. European Food Safety Authority (EFSA) has recently conducted a systematic study of published medical literature, focusing on the correlation between the intake of soy isoflavones and the induced effects on the breast (mammographic density, proliferative marker Ki67 expression), uterus (endometrial thickness, histopathology changes), and thyroid (the thyroid hormone). Results showed that the intake of 35–150 mg isoflavones/day does not affect these organs in peri- and postmenopausal women [17]. Isoflavones have demonstrated prostate cancer efficacy in several studies: in vitro, on prostate cancer cell lines, in vivo, and in numerous clinical trials [43, 67, 68]. Conclusion of a recent meta-analysis suggests that phytoestrogen intake, mostly genistein and daidzein, can be correlated with a decreased risk of prostate cancer [69].

Advertisement

5. Recent advances in analytical methods of isoflavones

5.1. Isolation of isoflavones in foods and vegetable materials

In recent years, due to the health benefits provided by isoflavones, higher attention has been paid to the analytical methods that allow identification and quantification of isoflavones from different types of samples: (a) food, for dietary intake assessing [15, 70]; (b) food supplements, for standardization of nutraceuticals [5, 71]; (c) vegetable products, for phytotherapeutic evaluation [19, 20, 28]; and (d) human biological samples (plasma, urine) [5]. These analytical methods are commonly used for isoflavone bioavailability assessing and in pharmacokinetic or pharmacological studies.

Isoflavones are solubilized from food or vegetable material by refluxing or maceration, shaking, and stirring [72]. The isolation of isoflavones from the mixture can be achieved either by conventional methods, liquid-liquid extraction [11, 15, 19] or Soxhlet, or by modern ones—supercritical fluid extraction, ultrasound-assisted extraction [19, 71], pressurized fluid extraction, microwave-assisted extraction, and solid-phase extraction [5, 73] (Table 4).

AnalytesSampleExtraction methodDetectionRun time (min)LOQReferences
3 IFsSoy dry extractSonication/Steam bathHPLC-DAD2040–100 ng/mL[71]
3 IFs, Cou*10 plant speciesUAE**ULPC-PDA41.97–4.08 ng/mL[19]
12 IFsSoybean seedsMacerationHPLC-UV60NA#[70]
12 IFsSoybeans, soy productsMacerationHPLC-DAD30<600 nmol/L[72]
3 IFsCoffeeRefluxingHPLC-DAD3513.7–25.0 ng/mL[14]
17 IFsSoymilkRefluxingLC-ESI(+)-MS/MSNA#NA#[74]
7 IFs, Cou*2 plant extractsRefluxing or MacerationLC-ESI(−)-MS/MS1840 ng/mL[20]
5 IFs, Cou*7 plant extractsMaceration or percolationULPC-ESI(+)-MS/MS5.55–10.78 ng/mL[28]
5 IFsLegumesSPE C18UHLPC-ESI(+)-MS/MS180.1–1 ng/mL[73]
5 IFsCoffeeSPE C18HPLC-ESI-MS/MS180.05–1 ng/mL[75]

Table 4.

HPLC and UPLC methods applied for analysis of isoflavones in different samples.

* Cou, coumestrol.

** UAE, ultrasound-assisted extraction.

# NA, not available.

The methods used to isolate isoflavones from food are selected function of the nature of the food, the type of the isoflavones analyzed (the total of aglycones or aglycones and glycosides), and the instrumental method used for identification and quantification. Several examples are presented below.

Liggins et al. isolated isoflavones from cereals and derivatives after a prior sonication in a polar solvent (methanol/water 4:1, v/v), in order to break apart the cellular material, followed by filtration and evaporation of the solvent under nitrogen. In order to determine the total aglycones, glycosides were hydrolyzed in an acid medium (0.1 M acetate buffer, pH 5) by overnight incubation at 37 °C in the presence of cellulase (enzyme used for hydrolytic removal of the hydrolysis resulted carbohydrates). Aglycones were extracted into ethyl acetate and were derivatized and analyzed using GC-MS [15]. Otieno et al. analyzed isoflavones from fermented and unfermented soy milk. For the solubilization of analytes, the freeze-dried sample was refluxed in methanol for 1 hour and filtered, and after adding the internal standard, the solvent has been evaporated to dryness under nitrogen. The residue has been suspended into a buffer (10 mm ammonium acetate containing 0.1% trifluoroacetic acid) and centrifuged, and the supernatant was filtered and analyzed using high-performance liquid chromatography (HPLC) [74].

Extraction and analysis of isoflavones in soybeans can be realized through maceration of the powdered beans with 70% ethanol at room temperature, for 24 hours under constant stirring. After centrifugation and filtering, the supernatant is analyzed directly by HPLC [70]. Also, analysis of isoflavones contained in food supplements requires a simple preparation of the samples: fine powdering of tablets, refluxing in 80% methanol for 1 hour, filtering, and injection into the HPLC system [5].

Hydroalcoholic extracts or tinctures can be prepared from either fresh or dry and pulverized vegetable materials. The hydroalcoholic extracts can be made in 70% ethanol or methanol, by refluxing and filtration; by cold maceration, pressing, and filtration [20]; by percolation [28]; or using modern methods, such as ultrasound-assisted extraction in 50% ethanol [19]. The extracts can be analyzed directly by LC-MS/MS, after an adequate dilution [20], or they can be subjected to an acid hydrolysis [19] in order to release aglycones. Further, the aglycones can be assessed directly or after liquid-liquid extraction, for a concentration of the analytes [19].

In biological samples (e.g., plasma and human urine) isoflavones can be found in different forms: as aglycones (active metabolites), aglycone derivatives (with or without bioactivity), or conjugated metabolites (β-glucuronides and sulfate esters). Isoflavone analysis can focus on individual quantification of aglycones and their metabolites or quantification of aglycones after the hydrolysis of conjugated forms. Hydrolysis of conjugated metabolites is achieved by incubation at 37 °C with a mixture of β-glucuronidase/sulfatase in the presence of a buffer (0.5 M acetate) at pH 4.5 for several hours or overnight. Isolation of free forms and/or of those freed after hydrolysis can be done by liquid-liquid extraction or solid-phase extraction [5].

5.2. Quantification of isoflavones in foods and vegetable materials

For isoflavone identification, the following chromatographic methods are used: gas chromatography coupled with mass spectrometry (GC-MS) [5, 15], high-performance liquid chromatography (HPLC) with UV detector (photodiode array, PDA) [28, 70, 71], fluorescence detector (FLD), electrochemical detector (ECD) or mass spectrometer detector (MS) [20, 74, 75], and, less often, capillary electrophoresis (CE).

Quantification of isoflavones and their derivatives can be achieved in two ways: (a) by determining the free aglycons after a prior acid hydrolysis [19, 70, 72], alkaline hydrolysis [72], or enzymatic hydrolysis [72] of the glycosides in the sample and (b) by simultaneously analyzing the glycosides and aglycones present in the sample [20, 28]. GC-MS methods are used less lately, because they require an additional step of isoflavone derivatization to the volatile compounds [5, 15]. This additional step increases both the time and the cost of the analysis and represents a potential source of error [28].

Generally, HPLC-UV is not sensitive enough (Table 4) for the quantification of small levels of isoflavones from plant extracts [19] or human plasma [5]. This method often requires a hydrolysis step to transform glycosides into aglycones followed by the quantification of total aglycones from the sample [71].

In order to correctly identify new isoflavones or isoflavone derivatives present in the samples analyzed, liquid chromatography coupled with mass spectrometry (LC-MS) and tandem mass spectrometry (LC-MS/MS) are the preferred methods (Table 4), due to the advantages: speed, selectivity, sensitivity, and robustness. In addition, mass spectrometry detection allows sure determination of the compounds based on molecular weight and ion charge. For the quantification of isoflavones, the pseudo-molecular ions or the ionic fragments resulted after fragmentation are monitored. In LC-MS/MS analysis, compound identification can be achieved even if their separation is not complete, and it is an advantage [74]. A shorter analysis can be realized by ultra-performance liquid chromatography (UPLC) [19, 28]. This method uses columns with very small size of the packing particles (1.7 μm) and consequently performs separations with superior resolution in a shorter time and a lower consumption of the mobile phase.

The isoflavones have polyphenolic structure and can easily lose a proton to form negative pseudo-molecular ions [M-H] [20]. However, they can also be detected after ionization in positive mode to [M + H]+ [74]. Isoflavones are polar compounds and they form ions in solution. For these type of compounds, electro-spray ionization (ESI) is the most commonly used source to obtain analytical ions. Atmospheric pressure chemical ionization (APCI) is the source preferred for non-polar analytes that ionize in the gas phase. The isoflavones often give poor response in this ionization source [28]. The fragmentation patterns of isoflavone glycosides (malonyl-glycosides, acetyl-glycosides, glycosides, aglycones) follow a similar trend. However each compound has a unique fragmentation pattern that allows their accurate identification (Table 5) [74].

Isoflavone[M + H]+Transitions[M − H]Tranzitions
Daidzein255 [28, 74]→199 [28]253 [20, 73, 75]→208, 132 [73, 75]
Formononetin269 [28]→197 [28]267 [20, 75]→252, 223 [75]
Genistein271 [28, 73, 74]→153 [28]269 [20, 73, 75]→159, 133 [73, 75]
Biochanin A283 [73, 75]→268, 239 [73, 75]
Glycitein285 [74]→270, 257, 229, 196, 166 [74]283 [20]
Daidzin417 [28, 73, 74]→255 [28, 73, 74], 199 [73]415 [20]→253 [20]
Ononin429 [20]→267 [20]
Genistin433 [28, 74, 75]→271 [28, 7375], 91 [73, 75]431 [20]→268, 269 [20]
Glycitin447 [74]→428, 285 [74]
Ac-daidzin459 [74]→441, 255 [74]
Ac-genistin475 [74]→431, 271 [74]
Ac-glycitin489 [74]→471, 285 [74]
Mal-daidzin503 [74]→485, 255 [74]
Mal-genistin519 [74]→501, 271 [74]

Table 5.

Ions (m/z) and transitions monitored for isoflavone quantification.

Advertisement

6. Conclusion

Dietary intake of isoflavones is widespread, mainly due to the high consumption of soybean products. Health benefits of isoflavones justify the interest for this class of bioactive compounds, but the controversial outcomes of some clinical and epidemiological studies require further investigations. In the context of these researches, the analytical methods applied for assessment of isoflavones are very valuable. They allow for the evaluation of dietary intake of isoflavones, equating the health benefits and the circumstances in which they are exerted, and highlight the natural sources of isoflavones with phytotherapeutic potential.

References

  1. 1. Tsao R. Chemistry and biochemistry of dietary polyphenols. Nutrients. 2010;2(12):1231–1246. Doi: 10.3390/nu2121231
  2. 2. Bolca S. Bioavailability of soy-derived isoflavones and human breast cancer. In: Watson RR, Preedy VR, Zibadi S, editors. Polyphenols in Human Health and Disease. Amsterdam: Elsevier; 2014. pp. 1241–1256. Doi: 10.1016/B978-0-12-398456-2.00094-3
  3. 3. Setchell KD, Brown NM, Zimmer-Nechemias L, Brashear WT, Wolfe BE, Kirschner AS, Heubi JE. Evidence for lack of absorption of soy isoflavone glycosides in humans, supporting the crucial role of intestinal metabolism for bioavailability. Am J Clin Nutr. 2002;76(2):447–453.
  4. 4. Cederroth CR, Nef S. Soy, phytoestrogens and metabolism: a review. Mol Cell Endocrinol. 2009;304(1–2):30–42. Doi: 10.1016/j.mce.2009.02.027
  5. 5. Setchell KD, Brown NM, Desai P, Zimmer-Nechemias L, Wolfe BE, Brashear WT, Kirschner AS, Cassidy A, Heubi JE. Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. J Nutr. 2001;131(4 Suppl):1362S–1375S.
  6. 6. Tolleson WH, Doerge DR, Churchwell MI, Marques MM, Roberts DW. Metabolism of biochanin A and formononetin by human liver microsomes in vitro. J Agric Food Chem. 2002;50(17):4783–4790.
  7. 7. Gaya P, Medina M, Sánchez-Jiménez A, Landete JM. Phytoestrogen metabolism by adult human gut microbiota. Molecules. 2016;21(8),1034:1-17. Doi: 10.3390/molecules21081034
  8. 8. Setchell KD, Clerici C. Equol: history, chemistry, and formation. J Nutr. 2010;140(7):1355S–1362S. Doi: 10.3945/jn.109.119776
  9. 9. Douglas CC, Johnson SA, Arjmandi BH. Soy and its isoflavones: the truth behind the science in breast cancer. Anticancer Agents Med Chem. 2013;13(8):1178–1187. Doi: 10.2174/18715206113139990320
  10. 10. Liggins J, Bluck LJ, Runswick S, Atkinson C, Coward WA, Bingham SA. Daidzein and genistein contents of vegetables. Br J Nutr. 2000;84(5):717–725.
  11. 11. Megías C, Cortés-Giraldo I, Alaiz M, Vioque J, Girón-Calle J. Isoflavones in chickpea (Cicer arietinum) protein concentrates. J Funct Foods. 2016;21:186–192. Doi: 10.1016/j.jff.2015.12.012
  12. 12. USDA Database for the Isoflavone Content of Selected Foods Release 2.1. 2015. https://www.ars.usda.gov/ARSUserFiles/80400525/Data/isoflav/Isoflav_R2-1.pdf.
  13. 13. Liggins J, Bluck LJ, Runswick S, Atkinson C, Coward WA, Bingham SA. Daidzein and genistein content of fruits and nuts. J Nutr Biochem. 2000;11(6):326–331.
  14. 14. Alves RC, Almeida IMC, Casal S, Oliveira MBPP. Method development and validation for isoflavones quantification in coffee. Food Chem. 2010;122:914–919. Doi: 10.1016/j.foodchem.2010.03.061
  15. 15. Liggins J, Mulligan A, Runswick S, Bingham SA. Daidzein and genistein content of cereals. Eur J Clin Nutr. 2002;56(10):961–966.
  16. 16. Patisaul HB, Jefferson W. The pros and cons of phytoestrogens. Front Neuroendocrinol. 2010;31(4):400–419. Doi: 10.1016/j.yfrne.2010.03.003
  17. 17. EFSA ANS Panel (EFSA Panel on Food Additives and Nutrient Sources added to Food). Scientific opinion on the risk assessment for peri- and post-menopausal women taking food supplements containing isolated isoflavones. EFSA J 2015;13(10):4246. Doi: 10.2903/j.efsa.2015.4246
  18. 18. Chang TS. Isolation, bioactivity, and production of ortho-hydroxydaidzein and ortho-hydroxygenistein. Int J Mol Sci. 2014 Apr 3;15(4):5699–5716. Doi: 10.3390/ijms15045699
  19. 19. Kiss B, Popa DS, Hanganu D, Pop A, Loghin F. Ultra-performance liquid chromatography method for the quantification of some phytoestrogens in plant material. Rev Roum Chim. 2010;55(8):459–465.
  20. 20. Vlase L, Popa DS, Tero-Vescan A, Olah N. New liquid chromatography: mass spectrometry assay for natural phytoestrogens from vegetable extracts. Acta Chromatogr. 2011;23:509–520.
  21. 21. Hanganu D, Vlase L, Olah N. LC/MS analysis of isoflavones from fabaceae species extracts. Farmacia, 2010;58(2):177–183.
  22. 22. Valls J, Millán S, Martí MP, Borràs E, Arola L. Advanced separation methods of food anthocyanins, isoflavones and flavanols. J Chromatogr A. 2009;1216(43):7143–7172. Doi: 10.1016/j.chroma.2009.07.030
  23. 23. Kicel A, Wolbiś M. Phenolic content and DPPH radical scavenging activity of the flowers and leaves of Trifolium repens. Nat Prod Commun. 2013;8(1):99–102.
  24. 24. Mu H, Bai YH, Wang ST, Zhu ZM, Zhang YW. Research on antioxidant effects and estrogenic effect of formononetin from Trifolium pratense (red clover). Phytomedicine. 2009 Apr;16(4):314–319. Doi: 10.1016/j.phymed.2008.07.005
  25. 25. Beck V, Rohr U, Jungbauer A. Phytoestrogens derived from red clover: an alternative to estrogen replacement therapy? J Steroid Biochem Mol Biol. 2005;94(5):499–518. Doi: 10.1016/j.jsbmb.2004.12.038
  26. 26. Grigorescu E, Ciulei I, Stanescu U. Index fitoterapeutic. Bucuresti: Editura Medicala; 1986. p. 252.
  27. 27. Bora KS, Sharma A. Phytochemical and pharmacological potential of Medicago sativa: a review. Pharm Biol. 2011;49(2):211–220. Doi: 10.3109/13880209.2010.504732
  28. 28. Kiss B, Popa DS, Păltinean R, Loghin F. A high-throughput UPLC-MS/MS for the simultaneous analysis of six phytoestrogens from Genista tinctoria extracts. J Liq Chromatogr Relat Technol. 2012;35(19):2735–2752.
  29. 29. Tero-Vescan A, Imre S, Vari CE, Osan A, Dogaru MT, Csedo C. Determination of some isoflavonoids and flavonoids from Genista tinctoria L. by HPLC-UV. Farmacia, 2009;57(1):120–127.
  30. 30. Rauter AP, Martins A, Lopes R, Ferreira J, Serralheiro LM, Araújo ME, Borges C, Justino J, Silva FV, Goulart M, Thomas-Oates J, Rodrigues JA, Edwards E, Noronha JP, Pinto R, Mota-Filipe H. Bioactivity studies and chemical profile of the antidiabetic plant Genista tenera. J Ethnopharmacol. 2009;122(2):384–393. Doi: 10.1016/j.jep.2008.10.011
  31. 31. Rigano D, Cardile V, Formisano C, Maldini MT, Piacente S, Bevelacqua Y, Russo A, Senatore F. Genista sessilifolia DC. and Genista tinctoria L. inhibit UV light and nitric oxide-induced DNA damage and human melanoma cell growth. Chem Biol Interact. 2009;180(2):211–219. Doi: 10.1016/j.cbi.2009.02.010
  32. 32. Popa DS, Bolfă P, Kiss B, Vlase L, Păltinean R, Pop A, Cătoi C, Crişan G, Loghin F. Influence of Genista Tinctoria L. or methylparaben on subchronic toxicity of bisphenol A in rats. Biomed Environ Sci. 2014;27(2):85–96. Doi: 10.3967/bes2014.021
  33. 33. Hanganu D, Olah NK, Benedec D, Mocan A, Crisan G, Vlase L, Popica I, Oniga I. Comparative polyphenolic content and antioxidant activities of Genista tinctoria L. and Genistella sagittalis (L.) Gams (Fabaceae). Pak J Pharm Sci. 2016;29(1 Suppl):301–307.
  34. 34. Hwang CS, Kwak HS, Lim HJ, Lee SH, Kang YS, Choe TB, Hur HG, Han KO. Isoflavone metabolites and their in vitro dual functions: they can act as an estrogenic agonist or antagonist depending on the estrogen concentration. J Steroid Biochem Mol Biol. 2006;101(4–5):246–253. Doi: 10.1016/j.jsbmb.2006.06.020
  35. 35. Pilšáková L, Riečanský I, Jagla F. The physiological actions of isoflavone phytoestrogens. Physiol Res. 2010;59(5):651–664.
  36. 36. Franco OH, Chowdhury R, Troup J, Voortman T, Kunutsor S, Kavousi M, Oliver-Williams C, Muka T. Use of plant-based therapies and menopausal symptoms: a systematic review and meta-analysis. JAMA. 2016;315(23):2554–2563. Doi: 10.1001/jama.2016.8012
  37. 37. Cheng PF, Chen JJ, Zhou XY, Ren YF, Huang W, Zhou JJ, Xie P. Do soy isoflavones improve cognitive function in postmenopausal women?. Meta Anal Menopause. 2015;22(2):198–206. Doi: 10.1097/GME.0000000000000290
  38. 38. Pawlowski JW, Martin BR, McCabe GP, McCabe L, Jackson GS, Peacock M, Barnes S, Weaver CM. Impact of equol-producing capacity and soy-isoflavone profiles of supplements on bone calcium retention inpostmenopausal women: a randomized crossover trial. Am J Clin Nutr. 2015;102(3):695–703. Doi: 10.3945/ajcn.114.093906
  39. 39. Cavallini DC, Manzoni MS, Bedani R, Roselino MN, Celiberto LS, Vendramini RC, de Valdez G, Abdalla DS, Pinto RA, Rosetto D, Valentini SR, Rossi EA. Probiotic soy product supplemented with isoflavones improves the lipid profile of moderately hypercholesterolemic men: a randomized controlled trial. Nutrients. 2016;8(1),52:1–18. Doi: 10.3390/nu8010052
  40. 40. Wong JM, Kendall CW, Marchie A, Liu Z, Vidgen E, Holmes C, Jackson CJ, Josse RG, Pencharz PB, Rao AV, Vuksan V, Singer W, Jenkins DJ. Equol status and blood lipid profile in hyperlipidemia after consumption of diets containing soy foods. Am J Clin Nutr. 2012;95(3):564–571. Doi: 10.3945/ajcn.111.017418
  41. 41. Chen M, Rao Y, Zheng Y, Wei S, Li Y, Guo T, Yin P. Association between soy isoflavone intake and breast cancer risk for pre- and post-menopausal women: a meta-analysis of epidemiological studies. PLoS One. 2014;9(2):e89288. Doi: 10.1371/journal.pone.0089288
  42. 42. Chi F, Wu R, Zeng YC, Xing R, Liu Y, Xu ZG. Post-diagnosis soy food intake and breast cancer survival: a meta-analysis of cohort studies. Asian Pac J Cancer Prev. 2013;14(4):2407–2412. Doi: http://dx.doi.org/10.7314/APJCP.2013.14.4.2407.
  43. 43. Zhang Q, Feng H, Qluwakemi B, Wang J, Yao S, Cheng G, Xu H, Qiu H, Zhu L, Yuan M. Phytoestrogens and risk of prostate cancer: an updated meta-analysis of epidemiologic studies. Int J Food Sci Nutr. 2016;9:1–15. Doi: 10.1080/09637486.2016.1216525
  44. 44. US Food and Drug Administration. Guidance for Industry: A Food Labeling Guide (11. Appendix C: Health Claims). 2013. http://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/LabelingNutrition/ucm064919.htm.
  45. 45. Azadbakht L, Kimiagar M, Mehrabi Y, Esmaillzadeh A, Hu FB, Willett WC. Dietary soya intake alters plasma antioxidant status and lipid peroxidation in postmenopausal women with the metabolic syndrome. Br J Nutr. 2007;98(4):807–813. Doi: 10.1017/S0007114507746871
  46. 46. Cha YS, Park Y, Lee M, Chae SW, Park K, Kim Y, Lee HS. Doenjang, a Korean fermented soy food, exerts antiobesity and antioxidative activities in overweight subjects with the PPAR-γ2 C1431T polymorphism: 12-week, double-blind randomized clinical trial. J Med Food. 2014;17(1):119–127. Doi: 10.1089/jmf.2013.2877
  47. 47. Popa DS, Hanganu D, Vlase L, Kiss B, Loghin F, Crişan G. Protective effect of Trifolium pratense extract on oxidative stress induced by bisphenol A in rats. Farmacia. 2014:62(2):341–349.
  48. 48. Lockwood B. Nutraceuticals. A Guide for Healthcare Professionals. Second edition, London: Pharmaceutical Press; 2007. pp. 192–200.
  49. 49. Spagnuolo C, Russo GL, Orhan IE, Habtemariam S, Daglia M, Sureda A, Nabavi SF, Devi KP, Loizzo MR, Tundis R, Nabavi SM. Genistein and cancer: current status, challenges, and future directions. Adv Nutr. 2015;6(4):408–419. Doi: 10.3945/an.114.008052
  50. 50. Kwon Y. Effect of soy isoflavones on the growth of human breast tumors: findings from preclinical studies. Food Sci Nutr. 2014;2(6):613–622. Doi: 10.1002/fsn3.142.
  51. 51. Casati L, Sendra R, Sibilia V, Celotti F. Endocrine disrupters: the new players able to affect the epigenome. Front Cell Dev Biol. 2015;3:37. Doi: 10.3389/fcell.2015.00037
  52. 52. Setchell KD, Clerici C. Equol: pharmacokinetics and biological actions. J Nutr. 2010;140(7):1363S–1368S. Doi: 10.3945/jn.109.119784
  53. 53. Gheldiu AM, Popa DS, Loghin F, Vlase L. Oxidative metabolism of estrone modified by genistein and bisphenol A in rat liver microsomes. Biomed Environ Sci. 2015;28(11):834–838. Doi: 10.3967/bes2015.116
  54. 54. Lee AJ, Mills LH, Kosh JW, Conney AH, Zhu BT. NADPH-dependent metabolism of estrone by human liver microsomes. J Pharmacol Exp Ther. 2002;300(3):838–849.
  55. 55. Eliassen AH, Missmer SA, Tworoger SS, Hankinson SE. Circulating 2-hydroxy- and 16alpha-hydroxy estrone levels and risk of breast cancer among postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2008;17(8):2029–2035. Doi: 10.1158/1055-9965.EPI-08-0262
  56. 56. Ziegler RG, Fuhrman BJ, Moore SC, Matthews CE. Epidemiologic studies of estrogen metabolism and breast cancer. Steroids. 2015;99(Pt A):67-75. Doi: 10.1016/j.steroids.2015.02.015
  57. 57. Morimoto Y, Conroy SM, Pagano IS, Isaki M, Franke AA, Nordt FJ, Maskarinec G. Urinary estrogen metabolites during a randomized soy trial. Nutr Cancer. 2012;64(2):307–314. Doi: 10.1080/01635581.2012.648819
  58. 58. Atkinson C, Skor HE, Dawn Fitzgibbons E, Scholes D, Chen C, Wähälä K, Schwartz SM, Lampe JW. Urinary equol excretion in relation to 2-hydroxyestrone and 16alpha-hydroxyestrone concentrations: an observational study of young to middle-aged women. J Steroid Biochem Mol Biol. 2003;86(1):71–77.
  59. 59. Lu LJ, Cree M, Josyula S, Nagamani M, Grady JJ, Anderson KE. Increased urinary excretion of 2-hydroxyestrone but not 16alpha-hydroxyestrone in premenopausal women during a soya diet containing isoflavones. Cancer Res. 2000;60(5):1299–1305.
  60. 60. McClain MR, Wolz E, Davidovich A, Bausch J. Genetic toxicity studies with genistein. Food Chem Toxicol. 2006;44(1):42–55.
  61. 61. Messina M. Impact of soy foods on the development of breast cancer and the prognosis of breast cancer patients. Forsch Komplementmed. 2016;23(2):75–80. Doi: 10.1159/000444735
  62. 62. Hu YC, Wu CT, Lai JN, Tsai YT. Detection of a negative correlation between prescription of Chinese herbal products containing coumestrol, genistein or daidzein and risk of subsequent endometrial cancer among tamoxifen-treated female breast cancer survivors in Taiwan between 1998 and 2008: a population-based study. J Ethnopharmacol. 2015;169:356–362. Doi: 10.1016/j.jep.2015.04.028
  63. 63. Braakhuis AJ, Campion P, Bishop KS. Reducing breast cancer recurrence: the role of dietary polyphenolics. Nutrients. 2016;8(9),547:1-15. Doi: 10.3390/nu8090547
  64. 64. Chavarro JE, Toth TL, Sadio SM, Hauser R. Soy food and isoflavone intake in relation to semen quality parameters among men from an infertility clinic. Hum Reprod. 2008;23(11):2584–2590. Doi: 10.1093/humrep/den243
  65. 65. D’Adamo CR, Sahin A. Soy foods and supplementation: a review of commonly perceived health benefits and risks. Altern Ther Health Med. 2014;20(Suppl 1):39–51.
  66. 66. You L, Sar M, Bartolucci EJ, McIntyre BS, Sriperumbudur R. Modulation of mammary gland development in prepubertal male rats exposed to genistein and methoxychlor. Toxicol Sci. 2002;66(2):216–225. Doi: 10.1093/toxsci/66.2.216
  67. 67. Hwang YW, Kim SY, Jee SH, Kim YN, Nam CM. Soy food consumption and risk of prostate cancer: a meta-analysis of observational studies. Nutr Cancer. 2009;61(5):598–606. Doi: 10.1080/01635580902825639
  68. 68. van Die MD, Bone KM, Williams SG, Pirotta MV. Soy and soy isoflavones in prostate cancer: a systematic review and meta-analysis of randomized controlled trials. BJU Int. 2014;113(5b):E119–E130. Doi: 10.1111/bju.12435
  69. 69. He J, Wang S, Zhou M, Yu W, Zhang Y, He X. Phytoestrogens and risk of prostate cancer: a meta-analysis of observational studies. World J Surg Oncol 2015;13:231. Doi: 10.1186/s12957-015-0648-9
  70. 70. Sun J, Sun B, Han F, Yan S, Yang H, Kikuchi A. Rapid HPLC method for determination of 12 isoflavone components in soybean seeds. Agric Sci China. 2011;10(1):70–77. Doi: 10.1016/S1671-2927(09)60291-1
  71. 71. César Ida C, Braga FC, Soares CD, Nunan Ede A, Pianetti GA, Condessa FA, Barbosa TA, Campos LM. Development and validation of a RP-HPLC method for quantification of isoflavone aglycones in hydrolyzed soydry extracts. J Chromatogr B Analyt Technol Biomed Life Sci. 2006;836(1–2):74–78. Doi: 10.1016/j.jchromb.2006.03.030
  72. 72. Shao S, Duncan AM, Yang R, Marcone MF, Rajcan I, Tsao R. Systematic evaluation of pre-HPLC sample processing methods on total and individual isoflavones in soybeans and soy products. Food Res Int. 2011;44:2425–2434. Doi: 10.1016/j.foodres.2010.12.041
  73. 73. Vila-Donat P, Caprioli G, Maggi F, Ricciutelli M, Torregiani E, Vittori S, Sagratini G. Effective clean-up and ultra high-performance liquid chromatography–tandem mass spectrometry for isoflavone determination in legumes. Food Chem. 2015;174:487–494. Doi: 10.1016/j.foodchem.2014.11.047
  74. 74. Otieno DO, Rose H, Shah NP. Profiling and quantification of isoflavones in soymilk from soy protein isolate using extracted ion chromatography and positive ion fragmentation techniques. Food Chem. 2007;105:1642–1651. Doi: 10.1016/j.foodchem.2007.04.036
  75. 75. Caprioli G, Navarini L, Cortese M, Ricciutelli M, Torregiani E, Vittori S, Sagratini G. Quantification of isoflavones in coffee by using solid phase extraction (SPE) and high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). J Mass Spectrom. 2016;51(9):698–703. Doi: 10.1002/jms.3802

Written By

Daniela-Saveta Popa and Marius Emil Rusu

Submitted: 24 May 2016 Reviewed: 25 October 2016 Published: 22 February 2017